Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;8(4):897-900.
doi: 10.1016/j.euf.2022.08.001. Epub 2022 Aug 10.

Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers

Affiliations

Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers

Linda A Okoth et al. Eur Urol Focus. 2022 Jul.

Abstract

A number of genomic classifiers are available to aid in shared decision-making for men with localized prostate cancer; however, there is no high-level evidence assessing their clinical utility. The two randomized controlled trials in this report prospectively evaluate the use of gene expression classifier testing at the time of cancer diagnosis and after surgical treatment.

PubMed Disclaimer

Figures

Fig. 1:
Fig. 1:
G-MINOR Trial Schema
Fig. 2:
Fig. 2:
G-MAJOR Trial Schema

References

    1. Hayes DF, Defining Clinical Utility of Tumor Biomarker Tests: A Clinician’s Viewpoint. J Clin Oncol, 2021. 39(3): p. 238–248. - PubMed
    1. Sargent DJ, et al., Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol, 2005. 23(9): p. 2020–7. - PubMed
    1. Simon RM, Paik S, and Hayes DF, Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst, 2009. 101(21): p. 1446–52. - PMC - PubMed
    1. AskMUSIC Risk Calculator. 5/2/2022]; Available from: https://askmusic.med.umich.edu/tools/prostate-cancer-treatment-options.

Publication types

Substances